Results 101 to 110 of about 7,389 (203)

Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells [PDF]

, 2006
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant cancers but there is little known ...
A Ibrahim, A Rennicke, AB Sandler, AP Jekunen, BA Jansen, BA Teicher, Britta K. Stordal, BS Burns, C Kollmannsberger, C Kollmannsberger, CR Culy, D Pectasides, D Pectasides, DC Marks, G Belvedere, G Lenz, G Tisman, GA Hospers, H Kawai, H Kuroda, HD Preisler, HD Preisler, IS Song, J Liu, JM Woynarowski, JM Woynarowski, K Suzukake, K Yamamoto, KV Grech, L Pendyala, L Poulain, M Abal, M Markman, M Mishima, Mary W. Davey, N Jain, N Savaraj, N Thatcher, O Rixe, P Chollet, P Soulie, PJ Kuppen, PR Twentyman, R Sockalingam, RD Christen, Ross A. Davey, S Hector, S Ohta, SG Chaney, SL Lai, SW Johnson, T Fojo, T Moritaka, T Tashiro, V Dieras, VL Locke, WS Hong, Z El Akawi, Z Wang   +58 more
core   +2 more sources

Pharmacokinetic and Pharmacodynamic Modeling of Clonidine and Midazolam for Sedation in Pediatric Intensive Care

Pediatric Anesthesia, Volume 35, Issue 12, Page 1053-1062, December 2025.
ABSTRACT Background Clonidine and midazolam are routinely used in the pediatric intensive care unit for pain and sedation management, but target concentration and optimal dose are poorly defined for both drugs. The CloSed study is a multicenter, double‐blind, randomized, active‐controlled noninferiority trial with a 1:1 randomization between clonidine ...
Maddlie Bardol, Yucheng Sheng, Manuel Baarslag, Adriana Ceci, Frank Dörje, Mari‐Liis Ilmoja, Peter Larsson, Per‐Arne Lönnqvist, Tuuli Methsvat, Pavla Pokorna, Wolfgang Rascher, Joost van Rosmalen, Michael Schroth, Alessandra Simonetti, Dick Tibboel, Irmgard Toni, Catherine Tuleu, Thomas M. K. Völkl, Brian J. Anderson, Stefan Wimmer, Joseph F. Standing, Antje Neubert, CloSed Consortium   +22 more
wiley   +1 more source

MRP4 regulates ENaC-dependent CREB/COX-2/PGE2 signaling during embryo implantation

Oncotarget, 2017
Multi-drug resistance protein 4 (MRP4), a potential chemotherapeutic target as well as a transporter for endogenous signaling molecules (e.g. prostaglandins), is known to be expressed in the endometrium, although its possible role(s) in the physiology of the endometrium remains unknown.
Chen, JJ, Wang, Y, Meng, XJ, Ruan, YC, Zou, F, Chan, HC   +5 more
openaire   +4 more sources

A Drosophila ABC transporter regulates lifespan.

PLoS Genetics, 2014
MRP4 (multidrug resistance-associated protein 4) is a member of the MRP/ABCC subfamily of ATP-binding cassette (ABC) transporters that are essential for many cellular processes requiring the transport of substrates across cell membranes.
He Huang, Ying Lu-Bo, Gabriel G Haddad
doaj   +1 more source

Multidrug resistance-associated protein 4 is a bile transporter of Clonorchis sinensis simulated by in silico docking

Parasites & Vectors, 2017
Background Multidrug resistance-associated protein 4 (MRP4) is a member of the C subfamily of the ABC family of ATP-binding cassette (ABC) transporters. MRP4 regulates ATP-dependent efflux of various organic anionic substrates and bile acids out of cells.
Fuhong Dai, Won Gi Yoo, Ji-Yun Lee, Yanyan Lu, Jhang Ho Pak, Woon-Mok Sohn, Sung-Jong Hong   +6 more
doaj   +1 more source

Genetic variants associated with gastrointestinal symptoms in Fabry disease. [PDF]

, 2016
Gastrointestinal symptoms (GIS) are often among the earliest presenting events in Fabry disease (FD), an X-linked lysosomal disorder caused by the deficiency of α-galactosidase A.
Agapito, Giuseppe, Altomare, Federica, Arbitrio, Mariamena, Borrelli, Osvaldo, Concolino, Daniela, Di Martino, Maria Teresa, Guzzi, Pietro Hiram, Nicoletti, Angela, Pensabene, Licia, Pisani, Antonio, Riccio, Eleonora, Sanseviero, Maria Teresa, Scionti, Francesca, Sestito, Simona, Talarico, Valentina   +14 more
core   +1 more source

Disruption of Bile Acid Metabolism in the Gut–Liver Axis Predisposes Mice to Inflammatory Bowel Disease

MedComm, Volume 6, Issue 10, October 2025.
An imbalance among bile acids, immune hemostasis, and microbes potentially contributes to increased susceptibility to IBD in a mouse model of PSC. This disruption can be mitigated by the administration of LCA and 3‐O‐LCA. Mechanistically, LCA and 3‐O‐LCA can antagonize T‐β‐MCA‐induced macrophage FXR inhibition and the resulting enhancement of Th17 ...
Hui Chang, Yang Jiang, Qiong Zhao, Zhen Su, Mingyang Chen, Qiufen He, Jingbo Lai, Yingru Jiang, Jing Zheng, Ruolang Pan, Jianzhong Shao, Robert Chunhua Zhao, Ye Chen   +12 more
wiley   +1 more source

Evidence of mature adipocyte proliferation regulated by proliferin [PDF]

, 2010
Despite much research, whether mature adipocytes proliferate remains controversial. Here, we examined 5-bromo-2′-deoxyuridine (BrdU)-labelling of mature adipocytes.
Aki Minami, Hideyuki Okada, Hiroyuki Morita, Ichiro Mori, Isao Nagano, Kazuo Kajita, Kei Fujioka, Masahiro Yamauchi, Masao Takemura, Mitsuru Seishima, Takahide Ikeda, Takayuki Hanamoto, Tatsuo Ishizuka, Toshiko Kajita, Wu Zhiliang, Yoshihiro Uno, Yuzo Takahashi   +16 more
core   +1 more source

Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies [PDF]

, 2019
The high selectivity of the human blood-brain barrier (BBB) restricts delivery of many pharmaceuticals and therapeutic antibodies to the central nervous system.
A Doran, A Herland, A Mahringer, A Regina, A Triantafyllou, A Wolff, AV Zhdanov, B Feng, B Oller-Salvia, B Rochat, B Srinivasan, BB Weksler, BD Gastfriend, BM Maoz, C Greene, EA Neuwelt, EG Geier, EK Hollmann, ES Lippmann, ES Lippmann, FC Thomas, FE O’Brien, GD Vatine, GL Semenza, H Abdollahi, H Burger, H Sade, HC Helms, JA Brown, JC Kalvass, JF Chen, JM Stenman, K Lauschke, KH Benam, KM Baeten, KS Kim, L Cucullo, L Tang, Louise Delsing, M Campisi, M Demeule, M Jorfi, M Li, M Ribecco-Lutkiewicz, ME Katt, ME Katt, MJ Stebbins, NJ Abbott, NR Wevers, OYF Henry, Q Wang, Q Zhang, R Cecchelli, R Daneman, R Shawahna, RM Linville, S Chakraborty, S Cisternino, S Kusuma, S Roman-Goldstein, S Sances, SN Bhatia, SW Lee, T Ohnishi, TR Doeppner, V Kiviniemi, W Löscher, W-L Yeh, WM Pardridge, WP Mason, Y Han, YI Wang, YJ Yu   +72 more
core   +1 more source

Development and Verification of Virtual Population Models for Predicting Drug Pharmacokinetics in Ethnic North American Populations

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 10, Page 1598-1615, October 2025.
ABSTRACT Ethnic variabilities can affect the outcome of drug pharmacokinetics (PK) and drug–drug interactions (DDI). This work aimed to develop four North American (NA) sub‐populations: White, African American, Asian American, and Hispanic_Latino suitable for physiologically based pharmacokinetic (PBPK) modeling and simulations.
Udoamaka Ezuruike, Jean Dinh, Eman El‐Khateeb, Alex Blenkinsop, Oliver Hatley, Iain Gardner   +5 more
wiley   +1 more source